TICKERNERD
Menu
AGENAGENHealthcare · Biotechnology

AGEN Stock Forecast: Agenus, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$7.09
−0.56% on the day

The 3 Wall Street analysts covering Agenus, Inc. hold a median 12-month price target of $25 — +252.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 28 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$300.3M
Ticker Nerd rank
86/ 100
Median analyst target
$25
Analysts covering
3
Revenue$34.5M+34.4% y/y
Operating income$11.3M
Net income−$567K
Free cash flow−$31.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.9%
1M
−28.3%
YTD
+125.8%
1Y
+84.2%
From 52W high
−28.6%
From 52W low
+156.0%
$2.77
$9.93
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Agenus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
86/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Quality
95
Value
95
Momentum
90
Issuance
69
Size
59
Accruals
43
Revisions
25
Volatility
16

Growth (99): Sales and profits are climbing, and climbing faster than before.

Volatility (16): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00Jan 26Apr 26Jul 26Oct 26AGENHigh $40Median $25Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $14Median $25High $40

The green dot is the last close — the median target sits +252.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
26 Oct 2026Chardan CapitalMaintainsBuy$40
22 Oct 2026Chardan CapitalMaintainsBuy$40
5 Oct 2026Chardan CapitalMaintainsBuy$40
5 Oct 2026Chardan CapitalMaintainsBuy—
28 Sept 2026Rodman & RenshawInitiatesBuy$19
28 Sept 2026Rodman & RenshawInitiatesBuy—
18 Sept 2026Chardan CapitalInitiatesBuy$40
18 Sept 2026Chardan CapitalInitiatesBuy—
11 Aug 2026HC Wainwright & Co.MaintainsBuy$30 → $25
11 Aug 2026HC Wainwright & Co.MaintainsBuy—
30 July 2026B. Riley SecuritiesMaintainsBuy$8.00 → $14
30 July 2026B. Riley SecuritiesMaintainsBuy—
13 July 2026HC Wainwright & Co.MaintainsBuy—
13 July 2026HC Wainwright & Co.MaintainsBuy$23 → $30
10 Sept 2025HC Wainwright & Co.ReiteratesBuy—
28 Aug 2025HC Wainwright & Co.ReiteratesBuy—
4 June 2025BairdMaintainsNeutral—
4 June 2025HC Wainwright & Co.UpgradeBuy—
13 May 2025BairdMaintainsNeutral—
13 May 2025HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AGEN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Agenus, Inc. returned +84.2% against +13.1% for the S&P 500, dividends included.

AGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26AGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+100.0%
Analysts raising
1
Analysts cutting
0
Fundamentals

Agenus, Inc. (AGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.6×

Cheaper than 69% of US stocks

Price / sales
2.3×

Cheaper than 48% of US stocks

Price / book
−1.3×

Cheaper than 95% of US stocks

EV / EBITDA
7.7×

Cheaper than 46% of US stocks

Growth & margins
Revenue growth (YoY)
34.4%

Higher than 80% of US stocks

Earnings growth (YoY)
34.4%

Higher than 68% of US stocks

Gross margin
57.2%

Higher than 70% of US stocks

Operating margin
32.7%

Higher than 88% of US stocks

Net margin
69.3%

Higher than 98% of US stocks

Returns & dividend
Return on equity
0.0%

Higher than 44% of US stocks

Return on assets
12.5%

Higher than 95% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Agenus, Inc. (AGEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Agenus, Inc. has a market value of $300.3M and an enterprise value of $314.6M.

  • Revenue in the twelve months to 30 June 2026: $132.7M. The latest quarter grew 34.4% year on year.

  • Net income over the same four quarters: $91.9M, a 69.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$98.5M.

  • Agenus, Inc. spent $54K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 44.8M.

  • Trailing P/E: 2.6×; forward P/E: −60.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Agenus, Inc. employs 81 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

AGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AGENAgenus, Inc.$300.3M86
TTRXTurn Therapeutics, Inc.$327.4M22
PRLDPrelude Therapeutics, Inc.$329.7M91
SCTXScribe Therapeutics, Inc.$330.9M2
XFORX4 Pharmaceuticals, Inc.$332.1M61
ALECAlector, Inc.$333.6M55
ENTAEnanta Pharmaceuticals, Inc.$336.4M91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Agenus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AGEN news & analysis

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Business Wire · 25 Oct 2026positive

Agenus reported early Phase 2 NEOASIS results for BOT plus BAL given before surgery in patients with locally advanced dMMR colon cancer. The headline states that 72% had no cancer remaining at surgery after six weeks of treatment.

Why it matters — The reported surgical findings provide an early update on Agenus’s BOT+BAL combination in a colon cancer study sponsored by the Netherlands Cancer Institute.

Agenus to Provide Third Quarter 2026 Financial Report and Development Update

Business Wire · 22 Oct 2026neutral

Agenus announced it will release its third-quarter 2026 financial results before the market opens on November 5, 2026. The release will cover recent progress advancing BOT+BAL toward the Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer.

Why it matters — AGEN watchers can expect a financial update and information on the company’s BOT+BAL development progress on the announced date.

Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial

MarketBeat · 20 Oct 2026neutral

Agenus is concentrating its BOT/BAL registration strategy on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III MSS colon cancer after ending funding for the BATTMAN study in later-line metastatic disease.

Why it matters — The shift identifies the clinical trial now central to Agenus’s BOT/BAL registration strategy and notes the discontinued funding of another study.

Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference

Business Wire · 9 Oct 2026neutral

Agenus announced that Zack Armen, its Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardan’s 10th Annual Healthcare Conference on October 20, 2026.

Why it matters — The conference appearance is an opportunity for investors following AGEN to hear from the company’s corporate development and investor relations leadership.

Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Business Wire · 8 Oct 2026positive

Agenus announced that Armenia’s Ministry of Health granted marketing authorizations for Botvymo (botensilimab) and Evamplix (balstilimab), approved in combination for adults with previously treated MSS metastatic colorectal cancer without active liver metastases.

Why it matters — The authorizations mark the first marketing approvals for Agenus’ BOT+BAL combination in this patient population.

FAQ

Frequently asked questions about AGEN stock

What is the AGEN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Agenus, Inc. have a median 12-month price target of $25, with estimates ranging from $14 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AGEN stock a buy right now?

Of the 3 analysts covering Agenus, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Agenus, Inc. 86 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AGEN?

As at 28 Oct 2026, Agenus, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will AGEN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +252.6% from the last close, and Ticker Nerd's factor model ranks Agenus, Inc. 86 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AGEN stock forecast for 2030?

No analyst covering Agenus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $40 over the next 12 months.

How has AGEN stock performed over the past year?

Agenus, Inc. returned +84.2% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Agenus, Inc. do?

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer.

What is the latest news on AGEN?

The most recent item we track (Business Wire, 25 Oct 2026): "Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026". Agenus reported early Phase 2 NEOASIS results for BOT plus BAL given before surgery in patients with locally advanced dMMR colon cancer. The headline states that 72% had no cancer remaining at surgery after six weeks of treatment.

Company

About Agenus, Inc.

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer. Agenus develops a pipeline of checkpoint antibodies, immune modulators, and combination regimens designed to help the immune system recognize and attack tumors. Its current portfolio also includes vaccine adjuvants and cell therapy programs, supported by proprietary discovery platforms and in-house manufacturing and clinical development capabilities. The company’s lead programs center on botensilimab and balstilimab, which are being advanced in multiple solid-tumor settings, including colorectal cancer and other difficult-to-treat cancers. Agenus also works through subsidiaries and partners to support adoptive cell therapies and adjuvant technologies, giving it a broad role across the immunotherapy value chain. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus Inc. remains a specialist developer in the cancer immunotherapy market.

CEO Dr. Garo H. Armen Ph.D. · 81 employees · United States · https://www.agenusbio.com